Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 18
GLP-1 telehealth prescribing for addiction
Telehealth firms are offering off-label GLP-1 drugs for addiction. Two semaglutide trials show a signal, but not approval or class-wide proof.
Tirzepatide and Retinopathy in Type 1
A chart review found similar proportions of new diabetic retinopathy with off-label tirzepatide and matched controls in type 1 diabetes.
Tirzepatide vs Semaglutide in Arthroplasty
A records study found similar early outcomes after knee or hip arthroplasty, with two uncertain differences appearing at two years.
Nanomedicine Weight Loss in Mice
A dextran nanomedicine reduced weight and body fat in mice without lower food intake. No human weight-loss evidence exists.
Incretins and Doxorubicin Heart Injury
A 2026 review found heart-protective signals for GLP-1 drugs and tirzepatide in rodents, with no eligible human studies.
Tirzepatide After Lumbar Fusion
A retrospective cohort links tirzepatide with fewer mechanical complications after lumbar fusion, but it cannot establish cause and effect.
Oral vs injectable incretins
What trial evidence can and cannot say when comparing oral orforglipron with injectable semaglutide and tirzepatide.
Reading a reply about the HISTORI trial
A new letter responds to a comment on the HISTORI semaglutide analysis. Its indexed record confirms correspondence, not the content of either letter.
Reading the Semaglutide Aspiration Reply
The semaglutide reply confirms scientific correspondence, but its indexed record contains no argument, rebuttal, or new patient data.
Can semaglutide reduce crime?
A planned 1,200-person US trial will test semaglutide for addiction recovery and track arrests, incarceration, housing and work.
ESSENCE Japanese Subgroup Readout
The Japanese ESSENCE subgroup broadly matched the main semaglutide MASH result, but its fibrosis estimate remained imprecise.
Semax and Selank blends: evidence gaps
No published human trial establishes that a Semax and Selank blend is effective or safe, or that it matches the compounds studied separately.